Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis.
Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis.
复制标题
非小细胞肺癌血浆和恶性胸腔积液中的可溶性 CD40：预后的潜在标志物
DOI：
10.1016/j.cdtm.2015.02.010
复制
发表时间：
2015-03
影响因子：
--
通讯作者：
Huang JA
中科院分区：
文献类型：
--
作者：
Mu CY;Qin PX;Qu QX;Chen C;Huang JA
可溶性 CD40 (sCD40) 是抗肿瘤反应和基于 CD40 的免疫疗法的潜在调节剂；然而，sCD40 在伴有恶性胸腔积液的非小细胞肺癌 (NSCLC) 患者中的水平和意义尚不清楚。 2008年1月至2010年1月期间，我院收治了48例肺癌患者。采集每位受试者的外周血和胸腔积液样本。测量血浆和恶性胸腔积液上清液中的 sCD40 水平。通过流式细胞术直接免疫荧光分析证实了 CD3t T 细胞上的 CD40L 表达。研究于2010年1月1日结束后对所有患者进行随访。NSCLC恶性胸腔积液患者的循环和胸腔积液中sCD40水平升高，这些升高的sCD40水平与晚期疾病和不良预后相关。这些发现表明，sCD40 升高可能在调节抗肿瘤反应中发挥作用，也可能是一个有用的预后标志物。
Soluble CD40 (sCD40) is a potential modulator for both antitumor responses and CD40-based immunotherapy; however the levels and significance of sCD40 in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion are unknown. Forty-eight patients with lung cancer were treated in our institutions from January 2008 to January 2010. Peripheral blood and pleural effusion samples were collected from each subject. sCD40 levels in plasma and malignant pleural effusions supernatant were measured. The CD40L expression on CD3t T-cells was confirmed by flow cytometric direct immunofluorescence analysis. All patients were followed up after the study ended on January 1, 2010. Patients with malignant pleural effusion of NSCLC had elevated circulating and pleural effusion levels of sCD40, and these elevated sCD40 levels were associated with advanced diseases and a poor prognosis. These findings indicate that elevated sCD40 may have a role in modulating antitumor responses and may also be a useful prognostic marker.